Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/24123
Title: | Safety and efficacy of doxorubicin-eluting superabsorbent polymer microspheres for the treatment of liver metastases from neuroendocrine tumours: preliminary results | Authors: | Bonne, Lawrence Verslype, Chris LAENEN, Annouschka Cornelissen, Sandra Deroose, Christophe M. Prenen, Hans Vandecaveye, Vincent Van Cutsem, Eric Maleux, Geert |
Issue Date: | 2017 | Publisher: | ASSOC RADIOLOGY & ONCOLOGY | Source: | RADIOLOGY AND ONCOLOGY, 51(1), p. 74-80 | Abstract: | Background. The aim of the study was to retrospectively evaluate the symptom control, tumour response, and complication rate in patients with liver-predominant metastatic neuroendocrine tumours treated with transarterial chemoembolization using doxorubicin-eluting superabsorbent polymer (SAP) microspheres. Patients and methods. Patients with neuroendocrine liver metastases who underwent hepatic transarterial chemoembolization using doxorubicin-eluting SAP-microspheres (50-100 pm Hepasphere/Quadrasphere Microsphere particles, Merit Medical, South Jordan, Utah, USA) were included in this study. Pre- and post-procedure imaging studies were evaluated to assess short and intermediate-term tumour response using modified RECIST criteria. Symptom relief and procedure-related complications were evaluated. Results. A total of 27 embolization procedures were performed on 17 patients. Twelve of 17 patients (70%) were symptomatic, including carcinoid syndrome (n = 8) and severe, uncontrollable hypoglycemia (n = 4). Eight of 12 patients (67%) had complete symptom relief, and the remaining 4 (33%) had partial relief. One patient developed ischemic cholecystitis (6%). No other hepatobiliary complications occurred. Short-term and intermediate-term imaging follow-up was available for 15/17 patients (88%) and 12/14 patients (86%) respectively. At short-term follow-up (< 3 months), 14 patients (93%) showed partial response and the remaining patient had progressive disease (7%). At intermediate-term imaging follow-up (> 3 months), partial response, stable disease and progressive disease were found respectively in 7 (58%), 3 (25%) and 2 (17%) patients. Conclusions. Chemoembolization with doxorubicin-eluting SAP-microspheres is a safe and effective treatment option for neuroendocrine liver metastases and is associated with a low complication rate. In particular, no clinically evident liver necrosis or bile duct complications were encountered. | Notes: | [Bonne, Lawrence; Cornelissen, Sandra; Vandecaveye, Vincent; Maleux, Geert] Univ Hosp Leuven, Dept Radiol, Herestr 49, B-3000 Leuven, Belgium. [Verslype, Chris; Prenen, Hans; Van Cutsem, Eric] Univ Hosp Leuven, Dept Gastroenterol & Hepatol, Leuven, Belgium. [Laenen, Annouschka] Katholieke Univ Leuven, Interuniv Ctr Biostat & Stat Bioinformat, Leuven, Belgium. [Laenen, Annouschka] Univ Hasselt, Hasselt, Belgium. [Deroose, Christophe M.] Univ Hosp Leuven, Dept Nucl Med, Leuven, Belgium. | Keywords: | neuroendocrine tumour; chemoembolization; drug-eluting beads; procedure-related complications;neuroendocrine tumour; chemoembolization; drugeluting beads; procedurerelated complications | Document URI: | http://hdl.handle.net/1942/24123 | ISSN: | 1318-2099 | e-ISSN: | 1581-3207 | DOI: | 10.1515/raon-2017-0007 | ISI #: | 000397080400010 | Category: | A1 | Type: | Journal Contribution | Validations: | ecoom 2018 |
Appears in Collections: | Research publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
bonne 1.pdf | Published version | 511.31 kB | Adobe PDF | View/Open |
SCOPUSTM
Citations
3
checked on Sep 2, 2020
WEB OF SCIENCETM
Citations
7
checked on Aug 11, 2024
Page view(s)
64
checked on Sep 6, 2022
Download(s)
106
checked on Sep 6, 2022
Google ScholarTM
Check
Altmetric
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.